Ne Drug firm Aurobindo Pharma on Friday said the US health regulator has revoked the voluntary action initiated (VAI) status for its Unit-IV facility in Hyderabad.
The company has received a communication that the inspection conducted by the US Food and Drug Administration (USFDA) at our Unit IV, from November 4 to 13, 2019 is “still open and under review, by way of rescinding the 90-day VAl letter that was issued by them on February 18, 2020,” Aurobindo Pharma said in a filing to BSE.
The USFDA had, in November 2019, issued a Form 483 with 14 observations after the inspection of Aurobindo Pharma’s Unit-IV, a general injectable formulation manufacturing facility.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.